SCHEMBL2276

SCHEMBL2276

[CH2]CC[C](F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3509815 0.77
SCHEMBL16527304 0.74
SCHEMBL13718650 0.71
SCHEMBL1726897 0.69
SCHEMBL245834 0.69
SCHEMBL708517 0.67
SCHEMBL6158049 0.65
SCHEMBL6158045 0.65
SCHEMBL13719305 0.64 LMNA (0.31)
SCHEMBL13718882 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289522-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC. 2012-11-15 US claimed
EP-2483252-A2 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS Amira Pharmaceuticals, Inc. (US) 2012-08-08 EP claimed
US-8217066-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2012-07-10 US claimed
WO-2011041694-A2 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 WO claimed
US-20110082181-A1 Compounds as Lysophosphatidic Acid Receptor Antagonists Amira Phamaceuticals, Inc. (US) 2011-04-07 US claimed
US-11932600-B2 Biaryl derivative DAIICHI SANKYO COMPANY LIMITED (JP) 2024-03-19 US disclosed
US-20210355087-A1 BIARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-11-18 US disclosed
US-9624182-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
US-9272990-B2 Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis AMIRA PHARMACEUTICALS, INC. (US) 2016-03-01 US disclosed
US-20150329502-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2015-11-19 US disclosed
EP-2648714-B1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2015-11-18 EP disclosed
US-9090573-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-6827876-B2 Using alpha, alpha -difluorocyclohexylidene derivative as starting material to obtain difluoromethyl ether derivative CHISSO CORPORATION (JP) 2004-12-07 US disclosed
US-20040016906-A1 Difluoromethyl ether derivative and process for producing the same JNC CORPORATION (JP) 2004-01-29 US disclosed
US-20040004207-A1 Difluoromethyl ether derivative and process for producing the same JNC CORPORATION (JP) 2004-01-08 US disclosed
WO-2003080054-A1 USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS FUJISAWA DEUTSCHLAND GMBH (DE) 2003-10-02 WO disclosed
EP-1348434-A1 Use of pyridyl amides as inhibitors of angiogenesis Fujisawa Deutschland GmbH (DE) 2003-10-01 EP disclosed
US-6605747-B2 Reacting the starting material, an alpha , alpha -difluorocyclohexylidene derivative with a halogen to produce an intermediate, reacting the intermediate with a phenol compound in presence of a base CHISSO CORPORATION (JP) 2003-08-12 US disclosed
US-20020120168-A1 Difluoromethyl ether derivative and process for producing the same JNC PETROCHEMICAL CORPORATION (JP) 2002-08-29 US disclosed
EP-1182186-A2 Difluoromethyl ether derivative and process for producing the same CHISSO CORPORATION (JP) 2002-02-27 EP disclosed